Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose.
about
Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive InfectionsProfile of oritavancin and its potential in the treatment of acute bacterial skin structure infectionsOritavancin diphosphateComparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial.Oritavancin: a new avenue for resistant Gram-positive bacteria.Investigational new drugs for the treatment of resistant pneumococcal infections.Oritavancin--an investigational glycopeptide antibiotic.Investigational treatments for postoperative surgical site infections.Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthraxOritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.Current challenges in treating MRSA: what are the options?Emergence and management of drug-resistant enterococcal infections.Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia.A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.Oritavancin: first global approval.Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections.Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review.Oritavancin: A Long-Half-Life Lipoglycopeptide.Oritavancin: a review in acute bacterial skin and skin structure infections.Oritavancin: a long-acting antibacterial lipoglycopeptide.Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic.Impact of human serum albumin on oritavancin in vitro activity against enterococci.Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections.Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides.Multiple-Dose Oritavancin Evaluation in a Retrospective Cohort of Patients with Complicated Infections.In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans.
P2860
Q26772897-DF736F28-07EE-4DFE-9AC4-C3D105351DD3Q26799701-B6AAB797-9A52-43AA-8BAF-094C2A9746E6Q35057973-9449DF27-8333-4150-B6FA-E3BA386F904EQ35065786-5B5EA04A-F760-4070-BF4D-805250E48363Q36162339-68CC4213-E368-49E1-B46D-E335D6588BF2Q36210902-D0BC4DF0-F1D4-4C01-8BAF-BB3577A4B451Q36426011-F881CF7C-A478-4E12-AF0B-36AE1711B04BQ36715742-FC71AE7C-8C1A-45CF-AE3C-FBA9324DB91EQ36870766-242076DC-E0B4-4C20-AC40-82D8FBF8D7E7Q37071199-989AB97C-4066-495F-97D8-B1EE6696FDF7Q37174100-7E63109C-A0C9-4B47-9935-8239DD64DEAFQ37291338-5EA12939-E3DE-44DF-9D64-6D47264BD454Q37291346-153DBB47-4D20-49B3-A7DD-A277D4C5A160Q37392932-2FDF8C7E-EF43-469E-A7F0-B125BF8FA092Q37661510-0DDD169E-A966-478B-8A6F-B7DCA104FC2BQ38252710-111AD7A3-1FC0-48E8-8777-BDB1F0E4845FQ38347765-3F7DAD76-4919-4C8D-862A-CB46811768B0Q38364691-E2AF7F66-A0FC-4296-A4C3-3F42B192AFC5Q38434265-12E52896-4355-436C-835D-DE0CC4B49525Q38606618-C7BCB0D1-D734-4E54-84B5-3AE0C0B5E634Q38830176-8BBF3CEA-452C-41DB-BFB8-66FCF2DE4781Q39164161-54BF3538-B612-4D48-B9D6-D8DA5E4C9BD4Q43121854-876D5DAB-9A8A-4AEA-B556-1D40FABF2FE8Q43169904-B8017350-7A1A-4691-8D21-FA588716E76AQ43834023-2547B3B8-5DFA-4DF6-8600-24ED4D7A5FA9Q46274310-B22DBE43-1325-4B5E-842C-3909F051644BQ50053159-783C723F-993A-4405-98FE-09736EB3DB8EQ50091622-6E19FF04-3D4C-46DC-848D-758B4AD7318DQ51760113-46F15E87-FDCC-40E9-AE71-18E1EEC51366
P2860
Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Pharmacokinetics of oritavanci ...... r a single 800-milligram dose.
@ast
Pharmacokinetics of oritavanci ...... r a single 800-milligram dose.
@en
Pharmacokinetics of oritavanci ...... r a single 800-milligram dose.
@nl
type
label
Pharmacokinetics of oritavanci ...... r a single 800-milligram dose.
@ast
Pharmacokinetics of oritavanci ...... r a single 800-milligram dose.
@en
Pharmacokinetics of oritavanci ...... r a single 800-milligram dose.
@nl
prefLabel
Pharmacokinetics of oritavanci ...... r a single 800-milligram dose.
@ast
Pharmacokinetics of oritavanci ...... r a single 800-milligram dose.
@en
Pharmacokinetics of oritavanci ...... r a single 800-milligram dose.
@nl
P2093
P2860
P1476
Pharmacokinetics of oritavanci ...... r a single 800-milligram dose.
@en
P2093
Christine M Ong
David P Nicolau
Gerald J Fetterly
Jeffrey S Loutit
Lisa G Morello
Paul G Ambrose
Steven B Porter
Sujata M Bhavnani
P2860
P304
P356
10.1128/AAC.49.1.148-152.2005
P407
P577
2005-01-01T00:00:00Z